Posted by Michael Wonder on 21 Nov 2016
Teva secures European approval of Trisenox for first-line treatment of low to intermediate risk acute promyelocytic leukaemia
21 November 2016 - Decision solely based on published academic data endorsing the benefit of Trisenox as first chemotherapy-free treatment for acute promyelocytic leukaemia and marks important advancement for patients in Europe.
Teva Pharmaceuticals today announced it has obtained approval from the European Commission for an indication extension of Trisenox (arsenic trioxide). This marks an important advancement in treatment for acute promyelocytic leukaemia (APL) patients in Europe, as it is the first time that a form of acute leukaemia can be effectively treated with a regimen that is entirely chemotherapy-free.
APL is a rare and aggressive type of acute leukemia that can kill within hours or days if left untreated. Trisenox, in combination with retinoic acid, has shown a 99% overall survival rate with almost no relapses after more than four years (50 months) of median follow-up.
